Introduction {#s1}
============

Oxidative stress has been implicated in a variety of both physiological (e.g. aging, differentiation, development, reproduction, cell cycle, apoptosis) and pathological processes (e.g. cancer, atherosclerosis, hypertension, diabetes, ischemia/reperfusion injury)([@R01]). Several studies have addressed its significant role as related to the classic concepts of initiation, promotion and progression of carcinogenesis([@R02]). Whether the tumorigenic effect of chronic oxidative stress depends on random mutations induced by reactive oxidative molecular species, or it is the result of some fragile genomic loci that are sensitive to oxidative damage in association with changes of transcriptional activity or other topologic or non-topologic effects remains to be explored.

Several studies have addressed the importance of oxidative stress in the evolution of colorectal cancer, demonstrating high oxidative stress either locally in the tumour area or systemically ([@R03]). In most of these studies, oxidative stress was demonstrated indirectly by increased lipid peroxidation and protein oxidation, decreased antioxidant substances and thiol groups, or decreased activity of antioxidant enzyme systems.

Superoxide radical (O~2~·^-^), resulting from the acceptance of one electron by molecular oxygen, is considered as the primary parameter of oxidative stress. Its formation *in vivo* in the blood of patients is of great clinical interest, because it directly shows the presence of oxidative stress. Superoxide's *in vivo* measurement, which has been problematic due to its short lifetime (∼ 1 microsecond) and its continuous detoxification by intra- and extracellular antioxidants ([@R01], [@R07]), can now be reliably done by application of a new ultrasensitive fluorescent assay developed by our team ([@R07], [@R08]).

The present study was undertaken to investigate directly oxidative stress in the blood of patients with early (non-metastatic) colorectal cancer by measuring O~2~^-^·.

Methods {#s2}
=======

Patients {#s2a}
--------

Twelve patients (6 males and 6 females) with a recent diagnosis of colorectal cancer and no signs of metastases and 12 healthy volunteers matched for age and gender were enrolled in the study. Colorectal cancer patients had histologically proven adenocarcinomas in biopsies taken during sigmo- or colonoscopy, and negative abdominal, chest and brain computed tomography scans for signs of metastases. They had not undergone any therapeutic intervention (surgery, chemotherapy or radiation therapy) before the time of blood sampling. Exclusion criteria were concomitant severe systemic diseases (diabetes mellitus, rheumatic diseases and cardiorespiratory insufficiency) or treatment during the last month with any medication known to affect oxidative stress parameters (vitamins C and E, allopurinol, N-acetyl-cysteine, corticosteroids, non-steroid anti-inflammatory drugs). Also patients and controls should have been non-smokers. During blood drawing no tourniquet constriction was used in order to minimize potentially enhanced oxidative stress induced by an ischaemia-reperfusion manoeuvre. All samples were taken using plastic syringes, and blood samples for oxidative stress measurements were placed in EDTA-containing tubes and immediately processed. The study was approved by the Ethics Committee of Patras University Hospital, Patras, Greece. Written informed consent was obtained from all subjects enrolled in the study.

Blood treatment for oxidative stress measurements {#s2b}
-------------------------------------------------

Whole blood samples (0.2 ml) were brought to 300 µM Hydroethidine (HE) \[O~2~^-^· specific trap\] by the addition of 2 µl 30 mΜ ΗΕ stock \[in 100% dimethyl sulfoxide (DMSO)\], and incubated at 37°C for 30 min. The HE-incubated whole blood was then centrifuged at 3,000 *g* for 5 min in order to separate plasma from blood cells. Blood plasma was treated for O~2~^-^· and protein determination. In another experiment, plasma was firstly separated from whole blood, then incubated with HE at 37°C for 30 min and processed for O~2~^-^· determination. For TBARS measurement, 0.2 ml HE-untreated whole blood was used because HE interferes with the TBARS assay ([@R09]).

O~2~^-^· assay {#s2c}
--------------

O~2~^-^· was assessed by application of a new ultrasensitive fluorescent assay, as previously described ([@R07], [@R08], [@R10]). O~2~^-^· concentration was expressed in pmole mg^-1^ protein (in 30 min).

TBARS assay {#s2d}
-----------

Plasma samples (approx. 50 µl) were assayed by a modified TBA-based method as described previously ([@R10]).

Protein concentration assay {#s2e}
---------------------------

Protein in approximately 400-fold diluted plasma sample was determined by a modification of a Coomassie Brilliant Blue-based method as described previously ([@R10]).

Statistical analysis {#s2f}
--------------------

Statistical analysis was performed using the SPSS statistical package (SPSS Inc, 2001, Release 11.0.0, USA). Results are expressed as mean ± SD and data were analyzed by non-parametric Mann-Whitney *U* test. A *P* value of less than 0.05 was considered significant.

Results {#s3}
=======

In the plasma fraction of the HE-treated whole blood, there was a significant increase (47%) of O~2~^-^· levels in colorectal carcinoma patients as compared to healthy volunteers (P \< 0.001) ([Fig. 1](#F1){ref-type="fig"}). When plasma was firstly separated from whole blood and then treated with HE, no O~2~^-^· was detected in both groups. Plasma TBARS levels were increased by 81% in colorectal carcinoma patient as compared to controls (P\<0.001) ([Fig. 2](#F2){ref-type="fig"}).

![O~2~^-^· levels in the plasma fraction of whole blood in healthy volunteers and patients with non-metastatic colorectal cancer. \*P\<0.001 as compared to controls.](gr-01-045-g001){#F1}

![Plasma lipid peroxide (TBARS) levels in healthy-controls and patients with non-metastatic colorectal cancer. \*P\<0.001 as compared to controls.](gr-01-045-g002){#F2}

Discussion {#s4}
==========

Colorectal cancer is a major global health problem and the fourth most common cause of cancer death worldwide([@R11]). Its aetiology is still under investigation, but a growing body of evidence has suggested that oxidative stress plays an important role in the molecular mechanism of colorectal cancer([@R04], [@R06], [@R12]). Colorectal cancer is generally assumed to be initiated by environmental genotoxic agents causing cellular overproduction of reactive oxygen species (ROS). As a consequence, extensive oxyradical-mediated damage can cause genetic alterations required for neoplastic progression and lead to a cycle of cell death and regeneration ([@R02], [@R15]).

To the best of our knowledge, this is the first study directly assessing O~2~·^-^ in the blood of patients with colorectal cancer. Our results demonstrate a significant increase of O~2~·^-^ in the plasma of patients with non-metastatic colorectal cancer as compared to healthy controls. This is a direct proof that patients with colorectal cancer, even at an early stage, are exposed to systemic oxidative stress. Moreover, oxidative stress was also shown indirectly by the 81% increase of the lipid peroxidation marker TBARS. Those aldehydic decomposition end products of lipid peroxides found increased in the plasma of colorectal carcinoma patients might have been formed (a) by the direct oxidative attack of serum blood lipids by O~2~^-^· (and other ROS derived from O~2~^-^·, such as hydroxyl radical) ([@R01]), and (b) locally in the cancerous tissue by increased ROS formation and then entering the systemic circulation and transported through blood to remote sites ([@R14], [@R16]).

Regarding the potential sources of increased plasma O~2~^-^· detected *ex vivo* in patients with non-metastatic colorectal cancer, there are some important points we would like to highlight. Firstly, increased O~2~·^-^ measured in the plasma of our patients could not have been the result of its potential increased production locally at the site of tumour growth ([@R14]), given its very short half-life (1 µs) and its inability to cross cell membranes ([@R01]). Secondly, O~2~^-^· was detected *ex vivo* only in the plasma fraction of HE-treated whole blood and not in the initially separated and then HE-treated plasma. This finding suggests that increased plasma O~2~^-^· in patients with colorectal cancer is most likely generated by blood cells and not by a source in the plasma per se (e.g. an activated soluble enzyme present in the plasma of patients with cancer). Previous studies have shown that in cancer O~2~·^-^ may be overproduced by: (a) activated granulocytes ([@R17]), (b) macrophages and natural-killer cells activated to react against the tumour ([@R18]), or (c) by malignant cells ([@R19]). Given that in the present study our patients had a non-metastatic cancer, which means that malignant cells are not possibly present in the systemic circulation, we are tempting to speculate that increased plasma O~2~·^-^ in those patients is possibly the result of its overproduction by activated circulating immune cells.

In conclusion, the present study shows that colorectal cancer, even at early (non-metastatic) stages, induces systemic oxidative stress as evidenced by increased O~2~·^-^ levels measured in plasma. Given the important role of oxidative stress in carcinogenesis and the fact that O~2~·^-^ is considered its primary parameter, our findings if confirmed in larger studies might establish the potential validity of O~2~·^-^ as a new biomarker for colorectal cancer.
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